Home > Insider Trading > Filing (0001144204-18-007440)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1042418	Hedgepath Pharmaceuticals Inc.	HPPI	Services-Commercial Physical & Biological Research (8731)	541641133

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1560183	Ltd Group Pharma Mayne	1538 Main North Road Salisbury South, Sa C3 5106	No	No	Yes	No
1611534	Ltd Pty International Pharma Mayne	1538 Main North Road Salisbury South, Sa C3 5106	No	No	Yes	No
1611535	Ltd Pty Ventures Pharma Mayne	1538 Main North Road Salisbury South, Sa C3 5106	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-12-19	600,000	$162,660.00	198,106,132	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

On December 19, 2017, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") acquired 600,000 shares of Common Stock from Stefan Cross.
These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.